Fitness and Alzheimer’s Risk: What the Evidence Shows

Higher cardiorespiratory fitness tracks with slower memory-related cognitive decline in people at elevated risk of Alzheimer's disease. Newer studies also link fitness with more favorable Alzheimer's biomarker profiles. That is useful news for anyone trying to protect long-term brain health. It is not proof that improving your VO2peak will slow amyloid buildup, tau spread, or Alzheimer's disease itself.

The distinction matters. Fitness may help people tolerate pathology longer, may correlate with healthier vascular and metabolic function, or may simply be easier to maintain before early disease affects the brain and body. Observational studies cannot fully separate those explanations.

The strongest result is about cognition, especially memory

The best direct cognitive evidence here comes from a longitudinal WRAP cohort study by Vesperman et al. The researchers studied 155 people at elevated risk for Alzheimer's disease and measured cardiorespiratory fitness with treadmill-derived VO2peak, the standard laboratory measure of aerobic capacity. They then tracked cognition over repeated assessments.

Participants with higher VO2peak showed slower age-related cognitive decline. The association was most apparent in factors weighted toward immediate memory, verbal learning and memory, visual learning and memory, and story recall. The result did not show a uniform benefit across every neuropsychological outcome.

That pattern fits what clinicians would expect from a study focused on preclinical Alzheimer's risk: episodic memory often changes before broad cognition does. Still, the study measured an association between baseline fitness and later cognitive trajectories. It did not randomly assign people to become fitter, so it cannot establish cause and effect.

Biomarker studies point toward resilience, not proven disease modification

A 2025 study by Paulsen et al. examined 533 cognitively unimpaired adults from the Wisconsin Alzheimer's Disease Research Center and Wisconsin Registry for Alzheimer's Prevention. Participants had a mean age of 65, 70% were women, and follow-up averaged 6.0 years. The investigators used sex-specific tertiles of estimated cardiorespiratory fitness rather than direct VO2peak testing.

Higher estimated fitness was associated with a lower risk of conversion to amyloid-beta positivity, more favorable biomarker profiles, and weaker relationships between Alzheimer's biomarker burden and subsequent cognitive decline on a modified PACC-3-type outcome. These findings support a resilience hypothesis: fitter people may show less cognitive impact at a given level of pathology.

Resilience is different from prevention. A person can maintain cognition longer despite amyloid or tau pathology without having less pathology in the first place. The study also used estimated fitness, which depends on a prediction equation and leaves more room for measurement error and residual confounding than treadmill-measured VO2peak.

Two newer studies extend the association into distinct genetic-risk settings. In KL-VS heterozygotes, Jarchow et al. found that greater fitness was associated with more favorable Alzheimer's-relevant biomarker profiles. In people with autosomal-dominant Alzheimer's disease, Guzmán-Vélez et al. linked higher fitness with plasma markers of pathology, markers of astrocyte reactivity, and cognition.

Those studies make a purely population-specific explanation less satisfying, but they do not erase the core problem. A genetic-risk cohort can still contain differences in vascular health, education, medication use, disease stage, mobility, and early symptoms that influence both fitness and brain outcomes.

A plausible brain pathway, with large gaps remaining

Fitness has a credible relationship with memory-relevant brain structure. Ripperger et al. reported associations between cardiorespiratory fitness, hippocampal subfield morphology, and episodic memory in older adults. The hippocampus is central to forming new memories, so the finding provides a plausible anatomical link between higher fitness and better memory performance.

Plausible does not mean proved. Brain structure, cognition, plasma biomarkers, and Alzheimer's pathology are related but distinct outcomes. An association with hippocampal morphology does not demonstrate that exercise changes the disease process that drives Alzheimer's dementia.

Blood biomarkers also require careful handling. Plasma p-tau217 and amyloid-beta 42/40 can identify amyloid risk with impressive diagnostic performance in several settings. For example, a Taiwan and Korea validation study found that p-tau217 outperformed p-tau181 among cognitively unimpaired participants, with areas under the curve of 0.921 and 0.769, respectively. Its low-risk and high-risk groups had negative and positive predictive values of 97.5% and 86.0%.

Those numbers validate p-tau217 as a useful risk-stratification tool in that study population. They do not show that a fitness-related difference in p-tau217 reflects a fitness-driven change in brain pathology. Biomarker performance also varies by population and context. Kidney function can influence Alzheimer's blood biomarker levels, as Arslan et al. reported, creating another possible explanation for part of a plasma-fitness association.

Why exercise trials have not settled the question

Cardiorespiratory fitness can improve with training in older adults, so a causal pathway is biologically possible. But the outcome that matters is whether raising fitness changes validated Alzheimer's biomarkers and ultimately slows meaningful cognitive decline.

That evidence is not yet in hand. A 2024 review by Sewell et al. examined exercise and blood-based Alzheimer's biomarkers in cognitively unimpaired older adults. The intervention evidence was inconsistent or null, and biomarker change did not clearly track with improvements in VO2peak. The review did not establish that exercise training changes blood biomarkers in a way that proves Alzheimer's disease modification.

Higher fitness is a credible marker of better cognitive aging and possible Alzheimer's resilience. It is not yet a validated disease-modifying Alzheimer's treatment.

Why might the observational and intervention literatures diverge? Trials may be too short, too small, or poorly matched to the stage when a biomarker could change. They may improve fitness without achieving the dose or duration needed to alter brain biology. Observational findings may also partly reflect reverse causation: early Alzheimer's pathology could reduce exercise tolerance or habitual activity before obvious cognitive impairment appears.

Biomarker trajectories add another complication. Kim et al. found that Alzheimer's biomarker timing differs by sex and APOE genotype. A single biomarker measurement, or a medium-term change, can therefore mean different things in different people.

What to do with this evidence

Cardiorespiratory fitness deserves attention because it consistently aligns with slower cognitive decline and better memory-related outcomes in Alzheimer's-risk cohorts. It also supports cardiovascular health, physical function, and metabolic health—outcomes that need no Alzheimer's-specific sales pitch.

Use fitness as a serious brain-health target and an observational marker of resilience, not as a substitute for Alzheimer's prevention or treatment. The next decisive studies will randomize people to programs that reliably increase cardiorespiratory fitness, measure validated biomarker changes, and follow cognition long enough to show whether those changes matter to patients. Until then, the honest claim is narrower: fitter people at elevated Alzheimer's risk tend to fare better, but science has not shown that fitness itself slows Alzheimer's disease.